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Objective: The reduced pressure in aircraft cabins may cause severe hypoxemia and respira-
tory distress in patients with chronic obstructive pulmonary disease (COPD). The primary
objective of this study was to determine the prevalence of in-flight symptoms in COPD patients
and non-COPD subjects, and evaluate associations between these symptoms and pre-flight
variables.
Methods: In a cross-sectional study of 391 COPD patients and 184 non-COPD subjects, we re-
corded lung function, blood gas values, exercise capacity, air travel habits and in-flight symp-
toms.
Results: Fifty-four percent of the COPD patients had travelled by air the last two years.
Hypoxia-related symptoms during air travel were experienced in 25% of the COPD patients
and 9% of the non-COPD subjects (p < 0.001). After adjusting for smoking status, age and
gender, the odds ratio for COPD patients to experience dyspnea or air hunger was 6.6 (95%
CI 2.5e17.3, p < 0.001) compared to non-COPD subjects. In the COPD patients, in-flight dys-
pnea or air hunger was strongly associated with pre-flight score on the Medical Research
Council (MRC) Dyspnea scale (p < 0.001).
Conclusion: COPD patients had significantly increased risk of in-flight dyspnea or air hunger
compared to non-COPD subjects. In COPD patients these symptoms were strongly associated
with pre-flight MRC Dyspnea score.
ª 2010 Elsevier Ltd. All rights reserved.7058289; fax: þ47 67075344.
littreklinikken.no (A. Edvardsen).
0 Elsevier Ltd. All rights reserved.
Figure 1 Flow chart of the subject selection. BCCS; Bergen
COPD Cohort Study.14
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Commercial airlines transport nearly two billion passengers
every year.1 At maximal cruising altitude, the cabin pres-
sure is allowed to decrease to the equivalent of 2438 m
altitude. This may cause a significant decrease in arterial
oxygen tension (PaO2) in patients with respiratory disease,
such as chronic obstructive pulmonary disease (COPD).1e6
Previous literature has focused on hypoxemia during air
travel,4,7e11 whereas data on in-flight symptoms are
limited. Two studies report symptoms in 18% of patients
with respiratory disease during air travel.12,13 These studies
lack comparison with healthy subjects. Moreover, it is not
known whether the occurrence of in-flight symptoms can be
predicted on the basis of pre-flight examination of the
patient.
Here we report a study on unselected, well character-
ized COPD patients and a group of subjects without COPD.
The primary objectives were to determine the prevalence
and kind of symptoms during air travel in COPD patients and
in a community sample, and to assess whether sea-level
values of lung function, arterial blood gases, exercise
dyspnea, walking distance or desaturation during exercise
were related to in-flight symptoms. Secondary aim was to
determine air travel habits.
Methods
Study design
The present cross-sectional survey included 433 COPD
patients and 233 subjects without COPD from the Bergen
COPD Cohort Study (BCCS). The patients were recruited
through outpatient clinics from several hospitals in Western
Norway, and from three private specialist practices in
Bergen (Norway).14 The control subjects were among
earlier participants of a large general population survey
from the same area.15
All COPDpatients hada smoking history of at least 10 pack-
years, post-bronchodilator FEV1/FVC<0.7, and FEV1<80%
predicted. The BCCS baseline visit in 2006 included clinical
examination, Medical Research Council (MRC) Dyspnea
scale16 scoring, arterial blood gas sampling, pulse oximetry,
and lung function testing. The COPD patients also performed
a 6-min walk test (6MWT).17 At the one-year follow-up visit,
we collected questionnaire data on air travel habits and
symptoms experienced during air travel within the previous
two years. Of the eligible subjects, 575 (86%) completed the
questionnaire and were included in the further analyses.
Written informed consent was obtained from all partic-
ipants. The study was approved by The Regional Committee
for Medical Research Ethics.
Questionnaire
The questionnaire included questions on air travel habits,
reasons for not flying (if applicable), number and duration
of flights within the last two years, pre-flight physician
consultation, and in-flight symptoms. Unscheduled use of
in-flight oxygen and healthcare within 48 h post-flight were
registered. Symptoms were classified as hypoxia related(dyspnea, dizziness, headache, chest pain, air hunger,
cough, fainting, palpitations) or hypoxia unrelated (ear
pressure, sinus pressure, swollen legs). Wording of the
questionnaire and alternatives for answering are given in
the Online supplement.
Pulmonary function testing, blood gas
measurement and functional walking test
Methods for spirometry and arterial blood gasmeasurements
were performed as previously described.14 Diffusing
capacity of the lung (DL,CO) and total lung volumes were
measured according to standardised criteria (SensorMedics
Vmax Encore, VIASYS Healthcare Respiratory Technologies,
Yorba Linda, USA).18,19 Reference values were based on
equations from the European Community for Coal and Steel,
or post-bronchodilator values from Johannessen et al.20,21
Dyspnea during the 6MWT was measured with the Borg
CR10 scale.17,22 Data for DL,CO, blood gases, MRC Dyspnea
scale, and 6MWTwere missing in 123 (21%), 40 (7%), 33 (6%),
37 (9%) subjects, respectively.
Statistical analysis
Chi-squared tests, two sample t-tests and Mann Whitney
tests were applied as appropriate. For identifying factors
associated with prevalence of symptoms, a logistic regres-
sion model was used. Adjustment was made for smoking,
age, and gender. A significance level of 5% was considered
as statistically significant. The analysis was performed with
SPSS version 16 (SPSS Inc., Chicago, IL, USA).
Results
Population characteristics, entire study group
Of the 575 subjects who completed the flight outcome
questionnaire, there were 391 COPD patients and 184 non-
COPD subjects (Fig. 1). The COPD group included signifi-
cantly more men, and had a higher mean age (Table 1).
According to the GOLD classification, 189 (48%), 141 (36%),
and 61 (16%) of the COPD patients were in GOLD stages II,
III, and IV, respectively.23
Table 1 Characteristics of study population.
COPD patients Subjects without COPD p-value
n Z 391 n Z 184
Sex, M/F 237/154 94/90 0.031
Age, yrs 62.9 (6.8) 53.8 (8.4) <0.001
BMI, kg/m2 25.5 (5.6) 26.0 (3.7) 0.196
Smoking habits <0.001
Never 0 31 (17)
Former 222 (57) 20 (11)
Current 169 (43) 133 (72)
FEV1, % of predicted 48.9 (14.1) 102.9 (9.4) <0.001
FEV1/FVC 0.46 (0.11) 0.79 (0.05) <0.001
DL,CO, % of predicted 58.5 (18.5) 84.0 (11.0) <0.001
RV/TLC, % 45.2 (10.3) 27.9 (6.8) <0.001
Blood gases and pulse oximetry
Pa,O2, kPa 9.3 (1.1) 10.8 (1.1) <0.001
Pa,CO2, kPa 5.3 (0.6) 5.2 (0.4) <0.001
Sp,O2, % 95.0 (1.2) 97.5 (2.7) <0.001
Six-minute walk test
Distance, m 432 (106) e e
End exercise Sp,O2, % 91.0 (5.8) e e
Dyspnea, Borg CR10 4.2 (3.0) e e
Data are presented as n (%), mean (SD). FEV1%predicted: post-bronchodilator forced expiratory volume in 1 s in percent of predicted;
FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; TLC: total lung capacity; RV: residual volume;
Pa,O2: arterial partial pressure of oxygen; Pa,CO2: arterial partial pressure of carbon dioxide; Sp,O2: arterial oxygen saturation by pulse
oximetry.
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years
Forty-six percent of the COPD patients did not travel by air,
compared to 13.6% of those without COPD (p < 0.001). The
COPD patients who did not fly were older, had more reduced
lung function, lower PaO2, a more pronounced exercise
desaturation and a shorter 6-minwalking distance than those
who flew (Table 2).
Of the 180 COPD patients who did not fly, 143 (79.4%) had
no reason to travel by air during the previous two years, 16
(8.9%) did not dare to fly due to their lung disease, 16 (8.9%)
stated other reasons (general fear of flying, economy, and
hypersensitivity to perfume), and 5 (2.8%) were advised by
a physician or other health professionals not to fly. As for the
subjects without COPD, one patient (4.0%) did not fly due to
fear of flying, and 24 (96.0%) reported no reason to fly.
Characteristics of COPD and non-COPD subjects
who flew
Two-hundred eleven (54.0%) of the COPD patients and 159
(86.4%) of those without COPD flew during the previous two
years (p < 0.001) (Fig. 2). During this period, 82.5% of the
COPD patients had two or more flights, with a most common
duration of 3e6 h (Fig. 2). The COPD patients travelled less
frequently than those without COPD (median number 2e4
flights vs. more than 4 flights, respectively, p < 0.001).
The COPD group had higher mean age and pre-flight MRC
Dyspnea score, and significantly lower FEV1% predicted,DL,CO% predicted, Pa,O2 and Sp,O2 than the non-COPD
subjects (Table 2).
Symptoms
Symptoms during air travel were more frequently experi-
enced in the COPD group (28.4%) than the non-COPD group
(16.4%) (ORZ 2.0, 95% CI 1.2e3.4, p < 0.001) (Fig. 3). One
or more hypoxia related symptoms were reported by 52
(24.6%) of the COPD patients and by 14 (8.8%) of the non-
COPD subjects (OR Z 3.4, 95% CI 1.8e6.4, p < 0.001)
(Fig. 3). The most frequent hypoxia related symptoms in
the COPD group were dyspnea and air hunger, which were
significantly higher in the COPD than in the group without
COPD (p < 0.001) (Table 3). There was no significant
difference between the groups with regard to symptoms
that were not hypoxia related; ear pressure, sinus pressure,
and swollen legs (OR Z 0.7, 95% CI 0.3e1.6) (Fig. 3).
After adjustment for confounders (smoking status, age,
and gender), patients with COPD had a more than 3-fold
higher risk of experiencing hypoxia related symptoms than
those without COPD (OR Z 3.3, 95% CI 1.6e6.7). For the
respiratory symptoms, dyspnea or air hunger, the risk was
nearly 7-fold higher (OR Z 6.6, 95% CI 2.5e17.3).
Associations between pre-flight parameters and in-
flight symptoms
Only the MRC Dyspnea score and exercise Sp,O2 showed
a significant relationship to in-flight dyspnea and air hunger
Table 2 Comparison of COPD patients who flew and did not fly and subjects without COPD who flew.
COPD patients n Z 391 Subjects without COPD n Z 184
Flew n Z 211 Did not fly n Z 180 P1) Flew n Z 159 P2)
Sex, M/F 124/87 113/67 0.419 80/79 0.106
Age, yrs 61.9 (6.7) 63.9 (6.7) <0.01 53.6 (8.6) <0.001
FEV1,% of predicted 51.6 (12.6) 45.7 (15.2) <0.01 103.0 (9.2) <0.001
DL,CO, % of predicted 61.4 (17.9) 54.7 (18.6) 0.001 84.3 (11.0) <0.001
RV/TLC, % 43.1 (9.2) 47.8 (11.0) <0.001 27.6 (6.8) <0.001
Blood gases and pulse oximetry
Pa,O2, kPa 9.5 (1.0) 9.1 (1.3) <0.001 10.8 (1.2) <0.001
Sp,O2, % 95.5 (2.3) 94.3 (3.0) <0.001 97.5 (1.2) <0.001
Six-minute walk test
Distance, m 459 (99) 401 (106) <0.001 e
End Sp,O2, % 92.0 (4.7) 89.9 (6.6) <0.001 e
MRC Dyspnea scale n Z 194 n Z 167 <0.001 n Z 157 <0.001
Stage 0 35 (18) 24 (14) 132 (84)
Stage 1 87 (45) 42 (25) 24 (15)
Stage 2 52 (27) 58 (35) 0
Stage 3 14 (7) 22 (13) 1 (1)
Stage 4 6 (3) 2 (1) 0
Data are presented as n (%) or mean (SD). FEV1%predicted: forced expiratory volume in 1 s in percent of predicted; DL,CO: diffusing
capacity of the lung for carbon monoxide; TLC: total lung capacity; RV: residual volume; Pa,O2: arterial partial pressure of oxygen;
Sp,O2: arterial oxygen saturation by pulse oximetry; MRC: modified Medical Research Council. -:test not performed. p
1) Z between
COPD patients who flew and did not fly; p2) Z between COPD patients who flew and subjects without COPD who flew.
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distance, there was a non-significant tendency towards
a relationship. A logistic regression model including age,
gender, MRC Dyspnea score, exercise desaturation, walking
distance, and DL,CO was used to study associations between
pre-flight variables and symptoms during air travel in
patients with COPD. The risk for experiencing dyspnea and
air hunger during flight was significantly related to the MRC
Dyspnea score. Level 2 or higher on the MRC Dyspnea scale
gave an OR 4.8 (95% CI 1.2e19.3) for in-flight dyspnea and air
hunger compared to MRC Dyspnea score 0. The OR for
experiencing in-flight dyspnea and air hunger was 0.93 (95%
CI 0.87e0.99) per year increase in age. No other statistically
significant associations were found.Figure 2 Frequency and duration of flights in COPD patients and s
COPD. *:p < 0.001.Use of in-flight oxygen and healthcare before and
after the flight
Before planning to travel by air, twenty-three (5.9%) of the
COPD patients had consulted a physician, while two (1.1%)
of those without COPD had a pre-flight physician consulta-
tion (p Z 0.007). Fourteen of the twenty-three COPD
patients were advised not to travel. Nine of those patients
travelled despite the physicians’ advice, and five of them
experienced hypoxia related symptoms. Eleven of the 391
COPD patients were on long-term oxygen therapy (LTOT).
Two of them flew, both with supplementary oxygen, and
none of them reported symptoms during air travel. Two of
the 209 patients without LTOT needed unscheduled use ofubjects without COPD.,: COPD patients,-: subjects without
Figure 3 Reported symptoms in COPD patients and subjects
without COPD. Values are given in percent of each group.
Overall symptoms: all symptoms reported. Hypoxia related
symptoms: dyspnea, dizziness, headache, chest pain, air
hunger, cough, fainting, and palpitations. Other symptoms (the
most frequent; ear pressure, sinus pressure, swollen legs).,:
COPD patients, -: subjects without COPD. *:p < 0.001.
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these patients were 9.6 kPa and 8.3 kPa, and their FEV1%
pred were 52% and 30%, respectively.
In the time span of 48 h after air travel, nine (4.3%) COPD
patients needed unscheduled healthcare, of these, four
(1.9%) were hospitalized. Four of the nine patients had
hypoxia related symptoms during flight. One of the subjects
without COPD was hospitalized after air travel, but the
subject in question did not report any symptoms duringflight.
Discussion
More than fifty percent of an unselected, western COPD
population had travelled by air during the previous two
years. One fourth of them experienced hypoxia related
symptoms during air travel, compared to nine percent of
individuals without COPD. The risk of experiencing dyspnea
or air hunger was almost seven times higher in the COPD
group than in those without COPD. In patients with COPD,
there was a strong association between in-flight dyspnea or
air hunger and sea-level MRC Dyspnea score. Desaturation
during 6MWT was also related to in-flight symptoms.
In 1991 and 1993 two studies from USA and Britain
reported that 44% and 35% of the COPDpatients had travelled
by air.12,24 In the present study, 54% of the COPD patients had
travelled by air, most of them more than once during theTable 3 Hypoxia related symptoms in COPD patients and subje
COPD patients n Z 211
Dyspnea 31 (14.7)
Air hunger 24 (11.4)
Cough 10 (4.7)
Headache 10 (4.7)
Dizziness 8 (3.8)
Palpitations 5 (2.4)
Chest pain 3 (1.4)
Fainting 1 (0.5)
Data are presented as n (%).previous two years. Taking into account the high and
increasing prevalence of COPD, the number of flight
passengers suffering from this disease is considerable and
likely to increase further.25
To our knowledge, this is the first flight outcome study
that compares COPD patients with non-COPD subjects. Our
data show a 3-fold increase in hypoxia related symptoms,
and a near 7-fold increase in dyspnea and air hunger.
Altogether, one fourth of the COPD patients experienced
hypoxia related symptoms during flight. We acknowledge
that symptoms classified as hypoxia related may have other
causes than hypobaric hypoxia. However, the occurrence of
other air travel related symptoms like ear pressure, sinus
pressure, and swollen legs did not differ between the
groups, indicating that the COPD patients were not more
prone to report symptoms in general.
Although the COPD population in the present study had
a milder disease than in the study by Coker et al, the prev-
alence of in-flight symptoms was higher. This discrepancy
can probably be explained by difference in patient selec-
tion.13 The patients in Coker’s study either used supple-
mentary oxygen during flight or, according to a respiratory
specialist assessment,werenot expected todevelop in-flight
hypoxemia. Thus, it seems reasonable to assume that the
prevalence of symptoms presented in the current study is
more representative for an unselected population of flight
passengers with COPD.
The difference in symptomprevalence between theCOPD
and the non-COPD group might have been influenced by
difference in age, gender and smoking habits. Correcting for
these parameters, however, did not influence the outcome
variables significantly.
In previous studies, the majority of COPD patients
reporting in-flight symptoms had severe hypoxemia during
subsequent testing with Hypoxia-altitude simulation test
(HAST).7,11 Thus, it seems reasonable to assume that the
symptomatic patients in the current study suffered from
hypoxemia, and that pre-flight testing would have resulted
in the use of supplementary oxygen. It should be noted,
however, that patients may become severely hypoxemic
during hypobaric and normobaric hypoxia without experi-
encing symptoms.4,5,7,10,26 Nine patients needed healthcare
after arrival, and almost half of those patients had symp-
toms during flight. It is worth noting that a large proportion
of those who travelled against the advice of their physician
experienced in-flight symptoms.
There are various methods for predicting in-flight hypox-
emia, but as far as we know, prediction of in-flight symptomscts without COPD.
Subjects without COPD n Z 159 p
2 (1.3) <0.001
4 (2.5) 0.001
3 (1.9) 0.140
6 (3.8) 0.651
1 (0.6) 0.084
2 (1.3) 0.703
0 (0.0) 0.263
1 (0.6) w1
Table 4 Characteristics of COPD patients who had or did not have dyspnea and air hunger, n Z 211.
n Had dyspnea and air hunger
n Z 44
n Did not have dyspnea and air
hunger n Z 167
p
Sex, M/F 44 22/22 167 102/65 0.228
Age, yrs 44 61.2 (6.8) 167 62.1 (6.7) 0.885
FEV1, % of predicted 44 46.2 (13.1) 167 48.9 (12.3) 0.197
DL,CO, % of predicted 38 56.8 (15.0) 151 62.5 (18.4) 0.077
RV/TLC, % 37 46.9 (7.5) 144 45.2 (7.9) 0.258
Blood gases and pulse oximetry
Pa,O2, kPa 42 9.4 (1.0) 162 9.5 (1.0) 0.746
Sp,O2, % 42 95.4 (2.4) 157 95.5 (2.3) 0.688
6 min walk test 41 147
Distance, m 435 (102) 466 (97) 0.077
End exercise Sp,O2, % 90.7 (5.9) 92.4 (4.3) 0.039
MRC Dyspnea scale 43 151 0.001
Stage 0 3 (7) 32 (21)
Stage 1 13 (30) 74 (49)
Stage 2 18 (42) 34 (23)
Stage 3 5 (12) 9 (6)
Stage 4 4 (9) 2 (1)
Data are presented as n (%), and mean (SD). FEV1% predicted: forced expiratory volume in 1 s in percent of predicted; DL,CO: diffusing
capacity of the lung for carbon monoxide; TLC: total lung capacity; RV: residual volume; Pa,O2: partial pressure of oxygen; Sp,O2:
arterial oxygen saturation; MRC: modified Medical Research Council.
Supplementary data
The supplementary data associated with this article can
be found in the on-line version at doi:10.1016/j.rmed.
2010.10.006.
Respiratory symptoms during air travel in COPD patients 55has not previously been studied.2,3,27Whereas lung function is
only weakly correlated with in-flight hypoxemia, exercise
related variables may give useful information for pre-flight
assessment.4,10,28 We evaluated the association between
these variables and the occurrence of in-flight symptoms. The
MRC Dyspnea score at sea-level was strongly associated with
in-flight dyspnea and air hunger. This is an interesting and not
previously described observation, which may be clinically
useful. Desaturation during a 6MWT also showed a significant
relationship with in-flight dyspnea and air hunger and
corroborates earlier observations of associations between
exercise desaturation and in-flight hypoxemia.28 Inclusion of
both MRC Dyspnea score and exercise desaturation may
possibly be valuable in pre-flight evaluation algorithms.
Itwould havebeenof interest toestablishwhether in-flight
symptoms were associated with development of hypoxemia
during HAST, but hypoxic challenge testing was not per-
formed. In addition, the current study has some other limi-
tations. The time between the measurements and air travel
could have been up to one year, and possible worsening of the
lung disease may have influenced the results. In addition, the
severity of the symptomswasnot recorded. Also, thedesign of
the study may give recall bias, which might result in under-
reporting of symptoms. On the other hand, a designwhere the
participants are asked to record respiratory distress during
actual flights might lead to increased symptom awareness,
and thereby over-reporting of symptoms. Although age and
gender differences between subjects with and without COPD
were corrected for in the analyses, these differences could
conceivably have influenced the results.
In conclusion, a large proportion of patients with
moderate to severe COPD travel by air. One fourth of them
reported hypoxia related symptoms during air travel. The
COPD patients had a near 7-fold higher risk of experiencingdyspnea or air hunger than those without COPD. The
symptoms were strongly associated with MRC Dyspnea
score, and an association between exercise desaturation
during a 6MWT was also observed. The high prevalence of
symptoms seems to justify pre-flight evaluation of COPD
patients. The optimal algorithm for this evaluation remains
to be established, but our results indicate that a symptom-
based approach in the pre-flight evaluation might be useful.
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